Table 3. Laboratory trends of the two HBV carriers with lamivudine resistance.
Participant | HBV DNA level (IU/ml) |
HBV Mutations | Serum ALT (IU/L) |
HIV RNA level (copies/ml) |
|
---|---|---|---|---|---|
22 | Month 0 | 280,000 | None | 24 | 614,000 |
Month 6 | 86 | None | 9 | 78 | |
Month 12 | 288 | A200V + M204I | 150 | 34 | |
Month 18 | 478,000,000 | A200V + M204I | 80 | 2 | |
| |||||
27 | Month 0 | 430,000,000 | None | 34 | 194,300 |
Month 6 | 3,407 | M204I | 39 | 26 | |
Month 12 | 2,027 | M204I | 28 | 14 | |
Month 18 | 576 | M204I | 38 | 84 |
HBV, hepatitis B virus. HIV, human immunodeficiency virus. ALT, alanine aminotransferase.